Business
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease MIAMI, Sept. 22, 2025 (GLO
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s disease","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Alzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trials","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Clear regulatory pathway following positive Type B meeting with U.S. FDA","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease","length":165,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":473,"olType":false},{"type":"text","content":"MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa taking place October 6-8, 2025 in Phoenix, Arizona.","length":390,"tagName":"p"},{"type":"text","content":"At the conference, members of the Longeveron management team will host meetings with global pharmaceutical company executives to explore potential partnership and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s disease (AD):","length":259,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive data from successful Phase 1 and Phase 2a AD clinical trials.","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Results from the Phase 2a clinical trial (CLEAR MIND), which support the therapeutic potential of laromestr...